On the stock market since 2021, it operates in the world of health and science. It has 14 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 61% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 105% a year on average.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 28/100.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, XOMAO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XOMAO is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.